Johanna Eriksson, Ph.D.

Senior Director, MIDD Consultant

Portrait-of-Johanna-Eriksson_Pharmetheus

Bio

  • Joined Pharmetheus in 2021, actively working in client projects and serving as deputy Project Portfolio Team Leader
  • Expertise includes physiological based pharmacokinetic modeling (PBPK) of preclinical and clinical data, especially for respiratory delivered medicines
  • M.Sc. (2015) and Ph.D. (2021) in Pharmaceutical Sciences from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Food effect prediction of high permeability/low solubility, formulated as an amorphous solid dispersion (ASD) using an open systems pharmacology (OSP) PBBM approachIntegrating in silico epitope prediction and mechanistic QSP modeling for benchmarking immunogenicity riskOpen-source PBPK modeling of artemether for pediatric extrapolations: integrating enzyme ontogeny, CYP2B6 auto-induction and malnutritionCoproporphyrin I PBPK model in the open systems pharmacology suite enables precise prediction of OATP 1B- mediated drug interactions through calibrated In vivo inhibition constantsModel-informed drug development of a sustained release formulation of flucytosine in the treatment of cryptococcal meningitis: a case study using physiologically based pharmacokinetic modelingPhysiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case studyOptimizing Formulations for Treatment of Cryptococcal Meningoencephalitis in Sub-Saharan HIV Patients: Insights from PBPK ModelingBioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitisPhysiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children.Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteers